BioprintingCosmetics Testing

BASF and CTIBiotech to develop first regenerating 3D bioprinted human skin model

The new 3D model will allow research and development of anti-inflammatory properties of active ingredients.

A research project involving BASF Care Creations and CTIBiotech has resulted in the development of the first 3D bioprinted human skin model including immune macrophages. The reconstructed tissue models will be the basis for the development and testing of bio-actives for skin care applications.

BASF has been very active in several segments of the 3D printing arena, with a previous bioprinting specific partnership with another French bioprinting company, Poietis. CTIBiotech has developed its own bioprinting technology to produce a 3D printed micro-tumor (used for highly significant pre-clinical trials) and advanced 3D skin models to test active ingredients, cosmetics, and dermatology products on advanced models, adding credibility to substantiate efficiency claims for customers.

Using CTIBiotech’s 3D bioprinting technology will enable BASF’s scientists to increase their 3D bioprinted skin model portfolio. The technology will provide a powerful platform for skincare researchers wishing to study the function of macrophages in a fully reconstructed skin.

Macrophages constantly monitor the skin’s microenvironment for indications of cell stress, tissue injury or infection. They are essential to close wounds and to fully regenerate tissue. To maintain skin homeostasis, macrophages have a high degree of plasticity that promotes or suppress inflammation.

“Compared to current in vitro methods, the 3D immune bioprinted skin developed with CTIBiotech will allow analysis more in line with human physiology and the immune role of macrophages,” said Dr. Sébastien Cadau, 3D tissue engineering specialist at BASF site in Lyon, France. “That’s how this technology is going to help us accelerate the development of innovative and highly reliable ingredients for the skincare market. Our understanding of an immunocompetent 3D skin provides the basis for developing and testing advanced cosmetic bio-actives for skincare applications.”

bioprinted human skin model
CTIBiotech’s 1 000 m² state of the art R&D facilities offer access to CTIBiosourcing and a highly trained team of international researchers located just 10 minutes from Lyon International Airport.

BASF and CTIBiotech started their cooperation as early as 2011. In 2015, the research partners started working on 3D tissue models for the development and testing of bio-actives for skincare applications. In 2018, they announced first results: The experts demonstrated both the ex vivo production of physiological sebum in long-term culture of a 3D human sebaceous gland model and the regulation of this sebum production by means of active ingredients.

“CTIBiotech and BASF have a long history of collaborations on innovative human skin models to advance human skincare,” said Prof Colin McGuckin, Chief Scientific Officer at CTIBiotech. “CTIBiotech hosts a team of world experts for human tissue engineering with 3D Bioprinting technology that will strengthen the success of this partnership also in the future.”

Tags

Davide Sher

Since 2002, Davide has built up extensive experience as both a technology journalist and communications consultant. Born in Milan, Italy, he spent 12 years in the United States, where he received his undergraduate degree. Specializing in covering the AM industry, he founded London-based 3D Printing Business Media Ltd. (now 3dpbm) which operates in marketing, editorial and market analysys&consultancy services for the additive manufacturing industry. 3dpbm publishes 3D Printing Business Directory, the largest global directory of companies related to 3DP, as well as several editorial websites, including 3D Printing Media Network and Replicatore. Since 2016 he is also a Senior Analyst for leading US-based firm SmarTech Analysis focusing on the additive manufacturing industry and relative vertical markets.

Related Articles

Leave a Reply

Your email address will not be published.

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!